Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients With Recurrent Glioblastoma (GBM)

  • STATUS
    Recruiting
  • End date
    Dec 31, 2024
  • participants needed
    94
  • sponsor
    Beijing Sanbo Brain Hospital
Send
Updated on 17 July 2021
See if I qualify

Summary

This study is intend to explore the efficacy and safety of combined treatment of camrelizumab and bevacizumab in adult patients with recurrent glioblastoma.

Description

There is no effective chemotherapy regimen for recurrent glioblastoma. The antiangiogenic drug bevacizumab has high objective response rate and rapid onset, but the duration of efficacy needs to be improved.The objective response rate of PD-1 monoclonal antibody immunotherapy is low and the onset of the effect is slow, but the effective patients have a long duration of efficacy.The combined treatment of PD-1 monoclonal antibody and bevacizumab may learn from each other to improve the effective rate, shorten the onset time and prolong the duration of efficacy.Studies have shown that bevacizumab can enhance the efficacy of immunotherapy in a variety of cancers, including melanoma, kidney cancer, non-small cell lung cancer, and liver cancer.However, previous studies have shown limited efficacy of PD-1 monoclonal antibody combined with bevacizumab in the treatment of recurrent glioblastoma.

In this study, the combination therapy was optimized by introducing induction phase therapy, which is expected to further improve the efficacy. In our previous exploratory treatment of patients with severe recurrent glioblastoma after multiple treatments, the initial efficacy was considerable.

The purpose of this study is to evaluate the efficacy and safety of camrelizumab [a programmed cell death 1 (PD-1) inhibitor] combined with bevacizumab for adult patients with recurrent glioblastoma.

Details
Condition Recurrent Glioblastoma
Treatment Camrelizumab and Bevacizumab
Clinical Study IdentifierNCT04952571
SponsorBeijing Sanbo Brain Hospital
Last Modified on17 July 2021

Eligibility

 Yes No Not Sure

Inclusion Criteria

Age 18~70, male or female
Primary supratentorial glioblastoma with first or second rogression/recurrence
IDH1/2 wildtype
KPS score 70 in patients with the first recurrence and 60 in patients with the second recurrence
Expected survival 12 weeks
The time interval from the last radiotherapy was 12 weeks, unless there was new tumor enhancement in the radiological field or clear evidence of tumor hipathology
Radiotherapy and at least one regimen of chemotherapy before recurrence (excluding temozolomide chemotherapy during concurrent radiotherapy)
The patients were enrolled after the end of the previous chemotherapy interval and had recovered from the related adverse reactions (except hair loss and pigmentation)
The tumor was confirmed to have definite recurrence by MRI, with enhanced lesion diameter 1cm and 2 layers (layer spacing 5mm), or was confirmed to have recurrence by pathology after re-biopsy or surgery
The time interval between the last operation and the last biopsy was 4 weeks or 2 weeks at the time of enrollment
The main organs function normally, no serious abnormal blood, heart, lung, liver, kidney function and immune deficiency diseases
Women of childbearing age are required to have a negative pregnancy test (serum or urine) within 7 days before enrolment and to voluntarily use contraception during treatment and within 8 weeks after the last treatment;For men, they should be surgically sterilized or agree to use contraception during treatment and for 8 weeks after the last treatment
Patients voluntarily enrolled in this study and signed informed consent (ICF)
Good compliance is expected, efficacy and adverse reactions can be followed up according to protocol requirements

Exclusion Criteria

Glioblastoma in the midline (thalamus, brainstem, sellar region, etc.)
Patients with initial recurrence had previously received long-term high-dose antiangiogenic drugs (except those with amlotinib or apatinib for less than 1 month and no progress during treatment, except those with intermittent bev dose intensity 5mg/ week and 3 times) or immunocheckpoint inhibitors, TCR-T, CAR-T, etc.;Patients with secondary recurrence had previously received long-term high-dose therapy of Bev (except for intermittent Bev dose intensity 5mg/ week and 3 times) or immunocheckpoint inhibitors, TCR-T, or CAR-T
Other study drugs are being used
An allergic reaction or intolerance to any component of the drug used in this study is known
Other malignant tumors in the past 3 years
Subjects who had been systematically treated with corticosteroids (>4mg/day dexamethasone or other equivalent hormone) or other immunosuppressants within 2 weeks prior to first use of carrelizumab.In the absence of active autoimmune disease, inhaled or topical corticosteroids and hormone replacement therapy with doses less than or equal to 4mg/ day of dexamethasone are permitted
The presence or history of any active autoimmune disease
Uncontrolled hypertension
Myocardial infarction occurred within 6 months prior to enrollment, New York Heart Society Class II heart failure or above, uncontrolled angina pectoris, uncontrolled severe arrhythmias, clinically significant pericardial disease, and electrocardiogram indicating acute ischemia or abnormal active conduction system
Abnormal coagulation function, bleeding tendency or receiving thrombolytic or anticoagulant therapy
Before entering the study 3 months there have been significant clinical significance of bleeding symptoms or have definite bleeding tendency;Or arterial/venous thrombosis events, such as cerebrovascular accidents, deep vein thrombosis and pulmonary embolism, occurred within 6 months before the study
Severe infection occurred within 4 weeks prior to initial administration;Or unexplained fever >38.5 during screening/prior to first administration
People who have a history of abuse of psychotropic substances and are unable to get rid of them or have mental disorders
Had major surgery or had an open wound or fracture within 4 weeks prior to first administration
Empty sinus passages or perforations were observed within 6 months prior to study entry
Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), active hepatitis B (HBVDNA500IU/ mL), hepatitis C (positive hepatitis C antibody and HCV-RNA above the detection limit of the assay method) or co-infection with hepatitis B and hepatitis C
Patients who received anti-tumor vaccine or other immunomodulatory drugs within 4 weeks before enrolment;Patients who have received or will receive live attenuated or recombinant vaccine within 4 weeks;Patients who received or will receive the inactivated vaccine within 1 week
Pregnancy and lactation
Other conditions that the investigator considered inappropriate for inclusion
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note